

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

NAIR et al

Serial No. 09/171,916

Filed: February 16, 1999



Confirmation No. 8645

Atty. Ref.: 1579-312

Group: 1636

Examiner: Guzo, D.

For: METHODS FOR TREATING CANCERS AND PATHOGEN INFECTIONS USING
ANTIGEN-PRESENTING CELLS LOADED WITH RNA

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 22, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO/SB/08a Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO/SB/08a together with copies (as may be required) of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. Also attached is a copy of the claims allowed in Application No. 09/875,264 ,

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

Atty. Docket No.

Serial No.

1579-312

09/171,916

Applicant

NAIR et al

Filing Date

TC/A.U.

February 16, 1999

1636

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

[illegible]


*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)



Atty. Docket No.

Serial No.

1579-312

09/171,916

Applicant

NAIR et al

Filing Date

TC/A.U.

February 16, 1999

1636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,256,536	10/1993	Miyada et al			

FOREIGN PATENT DOCUMENTS

						TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Alberts et al, "Either a DNA Probe or a Test for Expressed Protein Can Be Used to Identify the Clones of Interest in a DNA Library", Chapter 7, pg. 312, (1994), Molecular Biology of The Cell, Third Edition, Garland Publishing, Inc., New York & London
	Elson and Leder, "Protein-tyrosine Phosphatase ϵ , An Isoform Specifically Expressed in Mouse Mammary Tumors Initiated by v-Ha-ras OR neu", The Journal of Biology Chemistry 270(44):26116-26122 (1995)
	Nishikawa et al, "A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity", Proc. Natl. Acad. Sci. USA 91:7727-7731 (1994)
	Van den Eynde et al, "A New Family of Genes Coding for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on a Human Melanoma", J. Exp. Med. 182:689-698 (1995)
	Traversari et al, "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed against Tumor Antigen MZ2-E", J. Exp. Med. 176:1453-1457 (1992)
	van der Bruggen et al, "Autologous cytolytic T lymphocytes recognize a MAGE-1
	Kurpad et al, "Tumor antigens in astrocytic gliomas", Glia. 15(3):244-256 (1995) – Abstract
	Tokuraku et al, "Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis", Int. J. Cancer 64(5):355-359 (1995) – Abstract
	Guilloux et al, "A Peptide Recognized by Human Cytolytic T Lymphocytes on HLA-A2 Melanomas Is Encoded by an Intron Sequence of the N-Acetylglucosaminyltransferase V Gene", J. Exp. Med. 183:1173-1183 (1996)
	Inoue et al, "The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma", Gastroenterology 109(5):1522-1525 (1995) – Abstract
	Reist et al, "Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts", Cancer Research 55(19):4375-4382 (1995) – Abstract
	Boel et al, "BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes", Immunity 2(2):167-175 (1995) – Abstract

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.